Literature DB >> 19633202

Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.

Diane C Cabelof1, Hiral V Patel, Qing Chen, Holly van Remmen, Larry H Matherly, Yubin Ge, Jeffrey W Taub.   

Abstract

Down syndrome (DS) children have a unique genetic susceptibility to develop leukemia, in particular, acute megakaryocytic leukemia (AMkL) associated with somatic GATA1 mutations. The study of this genetic susceptibility with the use of DS as a model of leukemogenesis has broad applicability to the understanding of leukemia in children overall. On the basis of the role of GATA1 mutations in DS AMkL, we analyzed the mutational spectrum of GATA1 mutations to begin elucidating possible mechanisms by which these sequence alterations arise. Mutational analysis revealed a predominance of small insertion/deletion, duplication, and base substitution mutations, including G:C>T:A, G:C>A:T, and A:T>G:C. This mutational spectrum points to potential oxidative stress and aberrant folate metabolism secondary to genes on chromosome 21 (eg, cystathionine-beta-synthase, superoxide dismutase) as potential causes of GATA1 mutations. Furthermore, DNA repair capacity evaluated in DS and non-DS patient samples provided evidence that the base excision repair pathway is compromised in DS tissues, suggesting that inability to repair DNA damage also may play a critical role in the unique susceptibility of DS children to develop leukemia. A model of leukemogenesis in DS is proposed in which mutagenesis is driven by cystathionine-beta-synthase overexpression and altered folate homeostasis that becomes fixed as the ability to repair DNA damage is compromised.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633202      PMCID: PMC2756130          DOI: 10.1182/blood-2008-11-190330

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.

Authors:  Akira Shimada; Gang Xu; Tsutomu Toki; Hirokazu Kimura; Yasuhide Hayashi; Etsuro Ito
Journal:  Blood       Date:  2004-01-01       Impact factor: 22.113

2.  Brain isoprostanes: a marker of lipid peroxidation and oxidative stress in AD.

Authors:  Michael C Irizarry; Bradley T Hyman
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

3.  Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.

Authors:  Jeffrey W Taub; Gina Mundschau; Yubin Ge; Janet M Poulik; Faisal Qureshi; Tanya Jensen; S Jill James; Larry H Matherly; Joshua Wechsler; John D Crispino
Journal:  Blood       Date:  2004-09-01       Impact factor: 22.113

4.  Specific mutator effects of ung (uracil-DNA glycosylase) mutations in Escherichia coli.

Authors:  B K Duncan; B Weiss
Journal:  J Bacteriol       Date:  1982-08       Impact factor: 3.490

5.  DNA polymerase activity as an index of lymphocyte stimulation: studies in Down's syndrome.

Authors:  S S Agarwal; B S Blumberg; B J Gerstley; W T London; A I Sutnick; L A Loeb
Journal:  J Clin Invest       Date:  1970-01       Impact factor: 14.808

6.  Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia.

Authors:  Y Yao; V Zhukareva; S Sung; C M Clark; J Rokach; V M-Y Lee; J Q Trojanowski; D Praticò
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

7.  Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug.

Authors:  B A Kamen; P A Nylen; B M Camitta; J R Bertino
Journal:  Br J Haematol       Date:  1981-11       Impact factor: 6.998

8.  Decreased repair of x-ray induced DNA single-strand breaks in lymphocytes in Down's syndrome.

Authors:  K Athanasiou; E G Sideris; C Bartsocas
Journal:  Pediatr Res       Date:  1980-04       Impact factor: 3.756

9.  Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia.

Authors:  Victor Vitvitsky; Sanjana Dayal; Sally Stabler; You Zhou; Hong Wang; Steven R Lentz; Ruma Banerjee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-03-11       Impact factor: 3.619

10.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.

Authors:  Gang Xu; Masumi Nagano; Rika Kanezaki; Tsutomu Toki; Yasuhide Hayashi; Takeshi Taketani; Tomohiko Taki; Tetsuo Mitui; Kenichi Koike; Koji Kato; Masue Imaizumi; Isao Sekine; Yasuhiko Ikeda; Ryoji Hanada; Masahiro Sako; Kazuko Kudo; Seiji Kojima; Osamu Ohneda; Masayuki Yamamoto; Etsuro Ito
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

View more
  18 in total

1.  Transient abnormal myelopoiesis in a cytogenetically normal neonate.

Authors:  Kentaro Yanase; Keisuke Kato; Nobuko Katayama; Yoko Mouri; Chie Kobayashi; Junko Shiono; Masakazu Abe; Ai Yoshimi; Kazutoshi Koike; Jun-Ichi Arai; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

Review 2.  Acute leukemia in children with Down syndrome.

Authors:  Ana C Xavier; Jeffrey W Taub
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

3.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

4.  Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Roy G Rich; Michael J Hafez; Shuko Harada; Kathleen M Murphy; James R Eshleman; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

Review 5.  The role of DNA base excision repair in brain homeostasis and disease.

Authors:  Mansour Akbari; Marya Morevati; Deborah Croteau; Vilhelm A Bohr
Journal:  DNA Repair (Amst)       Date:  2015-05-01

6.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

7.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

Authors:  Amy P Hsu; Elizabeth P Sampaio; Javed Khan; Katherine R Calvo; Jacob E Lemieux; Smita Y Patel; David M Frucht; Donald C Vinh; Roger D Auth; Alexandra F Freeman; Kenneth N Olivier; Gulbu Uzel; Christa S Zerbe; Christine Spalding; Stefania Pittaluga; Mark Raffeld; Douglas B Kuhns; Li Ding; Michelle L Paulson; Beatriz E Marciano; Juan C Gea-Banacloche; Jordan S Orange; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

8.  Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.

Authors:  April D Sorrell; Todd A Alonzo; Joanne M Hilden; Robert B Gerbing; Thomas W Loew; Lois Hathaway; Dorothy Barnard; Jeffrey W Taub; Yaddanapudi Ravindranath; Franklin O Smith; Robert J Arceci; William G Woods; Alan S Gamis
Journal:  Cancer       Date:  2012-03-05       Impact factor: 6.860

Review 9.  Hematological disorders and leukemia in children with Down syndrome.

Authors:  Annelyse Bruwier; Christophe F Chantrain
Journal:  Eur J Pediatr       Date:  2011-11-24       Impact factor: 3.183

Review 10.  Myeloid leukemia in Down syndrome.

Authors:  Irum Khan; Sébastien Malinge; John Crispino
Journal:  Crit Rev Oncog       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.